Article
A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Lung cancer (Amsterdam, Netherlands) - 1 Jan 2017
Gow Chien-Hung, Hsieh Min-Shu, Wu Shang-Gin, Shih Jin-Yuan
Abstract excerpt
INTRODUCTION: Recurrent somatic splice-site alterations at MET exon 14 (METΔ14), which result in exon skipping and MET proto-oncogene, receptor tyrosine kinase (MET) activation, have been characterised. However, their demographic features and clinical outcomes in East Asian lung cancer patients have yet to be determined. METHODS: A one-step reverse transcription-polymerase chain reaction (RT-PCR), using RNA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.